Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer
- 1 September 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 168 (3) , 1001-1004
- https://doi.org/10.1016/s0022-5347(05)64560-0
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancerUrology, 1998
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostateAnti-Cancer Drugs, 1990
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- Can combined des and lhrh depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?Urology, 1988
- Zoladex (ICI 118,630): Clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinomaUrology, 1987
- Androgen Suppression by a Gonadotropin Releasing Hormone Analogue in Patients with Metastatic Carcinoma of the ProstateJournal of Urology, 1984
- Physiologic Basis for Hormonal Therapy in Carcinoma of the ProstateUrologic Clinics of North America, 1975